vTv azeliragon flunks mid-stage Alzheimer’s and diabetes study

 

• vTv Therapeutics (NASDAQ:VTVT) slumps 38% after-hours after announcing that its Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition relative to placebo.
• The trail included 43 people. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35.
• These differences were not statistically significant.
• Azeliragon was generally well-tolerated.
• https://seekingalpha.com/news/3644747-vtv-therapeutics-azeliragon-flunks-in-mid-stage-alzheimer-s-and-diabetes-study